Cerebral amyloid angiopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cerebral amyloid angiopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of Acetylcysteine Amide for Patients Aged 12 and Over with Hereditary Cystatin C Amyloid Angiopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-acetylcysteine-amide-for-patients-aged-12-and-over-with-hereditary-cystatin-c-amyloid-angiopathy-2/ Mon, 04 May 2026 07:55:56 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-acetylcysteine-amide-for-patients-aged-12-and-over-with-hereditary-cystatin-c-amyloid-angiopathy-2/ This clinical trial is focused on studying a rare condition called Hereditary Cystatin C Amyloid Angiopathy (HCCAA). This is a genetic disorder that can lead to problems with blood vessels in the brain, sometimes causing bleeding. The trial will test a new treatment called NPI-001, also known as acetylcysteine amide, which is taken as a tablet. The purpose of the study is to evaluate the safety, tolerability, and effectiveness of this treatment in patients with HCCAA.

Participants in the study will take the medication NPI-001 orally for a period of up to 12 months. During this time, they will have regular check-ups to monitor their health and any side effects. The study will also look at how often brain bleeding events occur in patients taking the medication. This will help researchers understand if the treatment can reduce these events and improve the condition.

Throughout the study, participants will undergo various assessments, including blood tests, skin biopsies, and MRI scans of the brain. These tests will help track changes in the body and the effects of the treatment. The study aims to provide valuable information on the potential benefits of NPI-001 for people with Hereditary Cystatin C Amyloid Angiopathy.

]]> Study on the Safety and Effects of ALN-APP for Patients with Cerebral Amyloid Angiopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-aln-app-for-patients-with-cerebral-amyloid-angiopathy/ Wed, 29 Apr 2026 15:04:12 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-aln-app-for-patients-with-cerebral-amyloid-angiopathy/ This clinical trial is focused on studying a neurological condition called Cerebral Amyloid Angiopathy (CAA). CAA occurs when amyloid proteins build up in the walls of blood vessels in the brain, which can lead to problems such as bleeding into the brain. The study will evaluate a treatment called Mivelsiran, which is administered as a solution for injection. Mivelsiran is also known by its code name ALN-APP. The purpose of the study is to assess the effect of Mivelsiran on the occurrence of new small brain bleeds, known as Cerebral Microbleeds (CMBs), in patients with CAA.

Participants in the study will receive either Mivelsiran or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The treatment will be given through a method called intrathecal use, which involves injecting the solution into the space around the spinal cord. The study will monitor participants over a period of time to observe any changes in the incidence of new CMBs and other related outcomes.

The study will also use MRI scans to detect changes in the brain and assess the safety and tolerability of Mivelsiran. MRI, or Magnetic Resonance Imaging, is a technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues in the body. The trial aims to provide valuable information on the potential benefits and risks of using Mivelsiran for treating CAA, contributing to a better understanding of how to manage this condition effectively.

]]> Study of [18F]MC225 to Assess P-glycoprotein Function in Patients with Alzheimer’s, Mild Cognitive Impairment, and Parkinson’s Disease https://clinicaltrials.eu/trial/study-of-18fmc225-to-assess-p-glycoprotein-function-in-patients-with-alzheimers-mild-cognitive-impairment-and-parkinsons-disease/ Wed, 29 Apr 2026 15:02:31 +0000 https://clinicaltrials.eu/trial/study-of-18fmc225-to-assess-p-glycoprotein-function-in-patients-with-alzheimers-mild-cognitive-impairment-and-parkinsons-disease/ This clinical trial is focused on studying certain brain conditions, specifically Alzheimer’s disease, Mild Cognitive Impairment, and Parkinson’s disease. The study will use a special substance called [18F]MC225, which is a solution for injection. This substance is designed to help researchers measure the function of a protein in the brain known as P-glycoprotein. Understanding how this protein works in these conditions may provide valuable insights into the diseases.

The purpose of the study is to evaluate how well [18F]MC225 can measure the activity of P-glycoprotein in the brain. Participants in the study will receive an injection of the substance, and then researchers will use imaging techniques to observe how it behaves in the brain. This process will help determine how the protein is functioning in individuals with the mentioned conditions.

Throughout the study, participants will undergo various imaging tests, such as PET scans, to track the uptake and movement of [18F]MC225 in the brain. These tests are non-invasive and will provide important data on cerebral blood flow and other brain functions. The study aims to gather information that could lead to better understanding and potentially improved treatments for these neurodegenerative diseases.

]]> Study on Vagus Nerve Stimulation and Sodium Oxybate for Patients with Cerebral Amyloid Angiopathy https://clinicaltrials.eu/trial/study-on-vagus-nerve-stimulation-and-sodium-oxybate-for-patients-with-cerebral-amyloid-angiopathy/ Wed, 29 Apr 2026 14:30:23 +0000 https://clinicaltrials.eu/trial/study-on-vagus-nerve-stimulation-and-sodium-oxybate-for-patients-with-cerebral-amyloid-angiopathy/ This clinical trial is focused on studying a condition known as cerebral amyloid angiopathy (CAA). CAA is a disease where protein deposits, called amyloid, build up in the walls of the blood vessels in the brain. This can lead to problems such as bleeding in the brain. The study is exploring whether two treatments, non-invasive vagus nerve stimulation (nVNS) and a medication called sodium oxybate, can help clear these amyloid deposits from the brain’s blood vessels. Sodium oxybate is a central nervous system depressant that is taken as an oral solution.

The purpose of the study is to see if these treatments can stimulate the brain’s cleaning system, known as the glymphatic system, to remove amyloid deposits more effectively. Participants in the study will receive either nVNS, sodium oxybate, or both. Some participants may receive a placebo. The study will last for a period of up to 12 months, during which the effects of the treatments will be monitored and compared to the participants’ condition before starting the treatment.

Throughout the study, participants will have regular check-ups to assess the levels of amyloid in their cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. This will involve a procedure called a lumbar puncture, where a small amount of fluid is taken from the lower back. The study aims to determine if the treatments can reduce amyloid levels and improve the condition of patients with cerebral amyloid angiopathy.

]]> Study on the Safety and Effects of Acetylcysteine Amide for Patients Aged 12 and Over with Hereditary Cystatin C Amyloid Angiopathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-acetylcysteine-amide-for-patients-aged-12-and-over-with-hereditary-cystatin-c-amyloid-angiopathy/ Wed, 29 Apr 2026 14:23:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-acetylcysteine-amide-for-patients-aged-12-and-over-with-hereditary-cystatin-c-amyloid-angiopathy/ This clinical trial is focused on studying a rare condition called Hereditary Cystatin C Amyloid Angiopathy (HCCAA). This is a genetic disorder that can lead to problems with blood vessels in the brain, sometimes causing bleeding. The trial will test a new treatment called NPI-001, which is also known as acetylcysteine amide. This treatment is taken as a tablet by mouth.

The purpose of the study is to see how safe and well-tolerated NPI-001 is for patients with HCCAA. Researchers will also look at how effective the treatment is in reducing the frequency of brain bleeding events compared to past rates. Additionally, the study will examine changes in certain proteins and markers in the skin, which are related to the disease, using advanced techniques.

Participants in the study will take the medication for up to 12 months. During this time, they will have regular check-ups, including skin biopsies and blood tests, to monitor their health and the effects of the treatment. The study will also involve MRI scans of the brain to assess any changes. The goal is to gather information that could help improve the understanding and management of HCCAA in the future.

]]>